$-0.52 EPS Expected for Syros Pharmaceuticals (SYRS); Quidel (QDEL) Sellers Increased By 3.54% Their Shorts

June 7, 2017 - By Michael Collier

Analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to report $-0.52 EPS on June, 19.After having $-0.47 EPS previously, Syros Pharmaceuticals Inc’s analysts see 10.64% EPS growth. The stock decreased 4.69% or $0.73 during the last trading session, reaching $14.83. About shares traded. Syros Pharmaceuticals Inc (NASDAQ:SYRS) has 0.00% since June 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Quidel Corporation (NASDAQ:QDEL) had an increase of 3.54% in short interest. QDEL’s SI was 3.35M shares in June as released by FINRA. Its up 3.54% from 3.24M shares previously. With 237,800 avg volume, 14 days are for Quidel Corporation (NASDAQ:QDEL)’s short sellers to cover QDEL’s short positions. The SI to Quidel Corporation’s float is 12.98%. The stock increased 0.20% or $0.05 during the last trading session, reaching $25.37. About shares traded. Quidel Corporation (NASDAQ:QDEL) has risen 56.78% since June 7, 2016 and is uptrending. It has outperformed by 40.08% the S&P500.

Since February 24, 2017, it had 0 buys, and 4 sales for $5.07 million activity. The insider BRYANT DOUGLAS C sold $899,160. On Monday, May 1 Bujarski Robert Joseph sold $1.05 million worth of Quidel Corporation (NASDAQ:QDEL) or 43,225 shares.

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The company has market cap of $838.13 million. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. It has a 247.27 P/E ratio. The Firm sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Among 7 analysts covering Quidel (NASDAQ:QDEL), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Quidel had 13 analyst reports since September 2, 2015 according to SRatingsIntel. PiperJaffray downgraded the shares of QDEL in report on Friday, December 16 to “Neutral” rating. The rating was downgraded by Raymond James to “Mkt Perform” on Monday, December 14. The rating was downgraded by Canaccord Genuity on Tuesday, February 9 to “Hold”. Barclays Capital initiated the shares of QDEL in report on Wednesday, September 2 with “Overweight” rating. The firm has “Buy” rating by Canaccord Genuity given on Friday, January 8. Piper Jaffray downgraded the shares of QDEL in report on Friday, December 16 to “Neutral” rating. On Friday, October 23 the stock rating was downgraded by Craig Hallum to “Hold”. The rating was upgraded by Raymond James to “Outperform” on Monday, June 13. The firm has “Neutral” rating given on Friday, February 17 by CL King.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: